- Report
- August 2026
- 150 Pages
Global
From €5485EUR$5,950USD£4,648GBP
- Report
- September 2026
- 182 Pages
Global
From €3268EUR$3,545USD£2,769GBP
€3631EUR$3,939USD£3,077GBP
- Report
- February 2026
- 250 Pages
Global
From €4139EUR$4,490USD£3,508GBP
- Report
- October 2026
- 367 Pages
Global
From €5393EUR$5,850USD£4,570GBP
- Clinical Trials
- August 2026
- 1100 Pages
Global
From €3180EUR$3,450USD£2,695GBP
- Report
- June 2026
- 200 Pages
Global
From €2756EUR$2,990USD£2,336GBP
- Report
- July 2026
- 200 Pages
Global
From €7366EUR$7,990USD£6,242GBP
- Report
- September 2026
- 324 Pages
Global
From €4424EUR$4,799USD£3,749GBP
- Report
- November 2025
- 474 Pages
Global
From €6591EUR$7,150USD£5,585GBP
- Report
- May 2026
- 141 Pages
Global
From €3687EUR$3,999USD£3,124GBP
- Report
- February 2026
- 250 Pages
Global
From €4139EUR$4,490USD£3,508GBP
- Report
- July 2026
- 265 Pages
Global
From €3826EUR$4,150USD£3,242GBP
- Report
- February 2026
- 250 Pages
Global
From €4139EUR$4,490USD£3,508GBP
- Report
- April 2026
- 200 Pages
Global
From €2756EUR$2,990USD£2,336GBP
- Report
- April 2026
- 200 Pages
Global
From €2756EUR$2,990USD£2,336GBP
- Report
- April 2026
- 200 Pages
Global
From €2756EUR$2,990USD£2,336GBP
- Report
- February 2026
- 200 Pages
Global
From €2756EUR$2,990USD£2,336GBP
- Report
- December 2025
- 200 Pages
Global
From €2756EUR$2,990USD£2,336GBP
- Report
- September 2026
- 199 Pages
Global
From €3268EUR$3,545USD£2,769GBP
€3631EUR$3,939USD£3,077GBP
- Report
- February 2026
- 250 Pages
Global
From €4139EUR$4,490USD£3,508GBP

Age-related Macular Degeneration (AMD) is a degenerative eye condition that affects the macula, the part of the eye responsible for central vision. It is the leading cause of vision loss in people over the age of 50. AMD is a major concern for the optical industry, as it can lead to severe vision impairment and blindness.
Optical companies are developing treatments and technologies to help diagnose and manage AMD. These include optical coherence tomography (OCT) imaging, which can detect early signs of AMD, and anti-VEGF drugs, which can slow the progression of the disease. Additionally, companies are developing new lenses and other optical devices to help improve vision in those with AMD.
Companies in the AMD market include Novartis, Regeneron, Allergan, Genentech, and Roche. Show Less Read more